Novartis weighs up IPO or spin-off of lossmaking eyecare division

Shares in Novartis closed 2.5% higher on Wednesday after it delivered its full year results presentation, in which it announced a share buyback programme and said it was considering options for its struggling eye care division Alcon, which makes contact lenses and eye medicines.